NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Dapagliflozin for Long COVID Syndrome

Not Yet RecruitingPhase 3

Sponsor: Ottawa Heart Institute Research Corporation

Conditions: COVID - 19, Long COVID Syndrome, SARS CoV-2

Interventions: Dapagliflozin (DAPA), Placebo

Countries: Canada

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* 18 years of age or older and willing and able to provide informed consent
* Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.
* New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).
* Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.

Exclusion Criteria:

* History of diabetes
* Prior heart failure
* Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)
* Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.
* Women who are breastfeeding
* Severe renal impairment (eGFR\<30mL/min1.73m2)
* Known history of allergy or hypersensitivity to dapagliflozin

Exclusion for optional MRI portion of the protocol:

\- Any contraindication to MRI

Locations (1)

Ottawa, Ontario, Canada